- Home
- INSM vs XPEV Comparison
INSM vs XPEV Comparison
Compare INSM & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- XPEV
- Stock Information
- Founded
- INSM 1988
- XPEV 2015
- Country
- INSM United States
- XPEV China
- Employees
- INSM N/A
- XPEV N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- XPEV Auto Manufacturing
- Sector
- INSM Health Care
- XPEV Consumer Discretionary
- Exchange
- INSM Nasdaq
- XPEV Nasdaq
- Market Cap
- INSM 17.3B
- XPEV 17.4B
- IPO Year
- INSM 2000
- XPEV 2020
- Fundamental
- Price
- INSM $98.24
- XPEV $18.39
- Analyst Decision
- INSM Strong Buy
- XPEV Buy
- Analyst Count
- INSM 17
- XPEV 8
- Target Price
- INSM $106.80
- XPEV $22.46
- AVG Volume (30 Days)
- INSM 6.2M
- XPEV 6.7M
- Earning Date
- INSM 08-07-2025
- XPEV 08-19-2025
- Dividend Yield
- INSM N/A
- XPEV N/A
- EPS Growth
- INSM N/A
- XPEV N/A
- EPS
- INSM N/A
- XPEV N/A
- Revenue
- INSM $381,030,000.00
- XPEV $6,908,129,404.00
- Revenue This Year
- INSM $28.03
- XPEV $100.77
- Revenue Next Year
- INSM $120.54
- XPEV $35.72
- P/E Ratio
- INSM N/A
- XPEV N/A
- Revenue Growth
- INSM 20.77
- XPEV 51.03
- 52 Week Low
- INSM $60.40
- XPEV $6.60
- 52 Week High
- INSM $106.83
- XPEV $27.16
- Technical
- Relative Strength Index (RSI)
- INSM 62.07
- XPEV 45.00
- Support Level
- INSM $98.85
- XPEV $17.71
- Resistance Level
- INSM $106.83
- XPEV $18.57
- Average True Range (ATR)
- INSM 3.17
- XPEV 0.52
- MACD
- INSM -0.86
- XPEV -0.07
- Stochastic Oscillator
- INSM 20.61
- XPEV 29.61
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.